• Company
• JAK inhibitor 'Jyseleca' approved for use at 'Big 5'
• by Eo, Yun-Ho Sep 13, 2024 05:50am

• Policy
• Moderna’s COVID-19 vaccine is approved in Korea
• by Lee, Hye-Kyung Sep 13, 2024 05:50am

• InterView
• ‘Era of once-weekly growth hormones…adherence is key’
• by Hwang, Byung-woo Sep 13, 2024 05:49am

• Company
• Global guidelines recommend Leclaza combination therapy
• by Son, Hyung-Min Sep 13, 2024 05:49am

• Company
• Hugel offers guide to safe injection of dermal fillers
• by 어윤호 Sep 12, 2024 04:16pm

• Company
• Yuhan earns ₩80B milestone with Leclaza's FDA nod
• by Chon, Seung-Hyun Sep 12, 2024 05:51am

• Company
• HK inno.N signs supply deal with Pfizer for COVID-19 vaccine
• by Son, Hyung-Min Sep 12, 2024 05:51am

• Company
• Celltrion aims for KRW 5T sales with 'ADC‧CDMO'
• by Hwang, Byung-woo Sep 12, 2024 05:51am

• Company
• Switching between JAKis reimbursed for rheumatoid arthritis
• by Eo, Yun-Ho Sep 12, 2024 05:50am

• Company
• LG Chem appeals... starts 2nd patent trial for Zemiglo
• by Kim, Jin-Gu Sep 12, 2024 05:50am